Abstract | BACKGROUND/AIM: METHODS: Intestinal biopsy specimens, isolated lamina propria cells (LPMC), and peripheral blood mononuclear cells (PBMC) were cultured with or without butyrate for assessment of secretion of tumour necrosis factor (TNF) and mRNA levels. NFkappaB p65 activation was determined by immunofluorescence and gene reporter experiments. Levels of NFkappaB inhibitory protein ( IkappaBalpha) were analysed by western blotting. The in vivo efficacy of butyrate was assessed in rats with trinitrobenzene sulphonic acid (TNBS) induced colitis. RESULTS: CONCLUSIONS:
Butyrate decreases proinflammatory cytokine expression via inhibition of NFkappaB activation and IkappaBalpha degradation. These anti-inflammatory properties provide a rationale for assessing butyrate in the treatment of CD.
|
Authors | J P Segain, D Raingeard de la Blétière, A Bourreille, V Leray, N Gervois, C Rosales, L Ferrier, C Bonnet, H M Blottière, J P Galmiche |
Journal | Gut
(Gut)
Vol. 47
Issue 3
Pg. 397-403
(Sep 2000)
ISSN: 0017-5749 [Print] England |
PMID | 10940278
(Publication Type: Journal Article)
|
Chemical References |
- Butyrates
- Gastrointestinal Agents
- Interleukin-1
- Interleukin-6
- NF-kappa B
- RNA, Messenger
- Tumor Necrosis Factor-alpha
|
Topics |
- Adolescent
- Adult
- Aged
- Animals
- Blotting, Western
- Butyrates
(therapeutic use)
- Cells, Cultured
- Crohn Disease
(drug therapy, metabolism)
- Dose-Response Relationship, Drug
- Drug Evaluation
- Female
- Gastrointestinal Agents
(therapeutic use)
- Humans
- Interleukin-1
(metabolism)
- Interleukin-6
(metabolism)
- Leukocytes, Mononuclear
(drug effects, metabolism)
- Male
- Middle Aged
- NF-kappa B
(drug effects, metabolism)
- Prospective Studies
- RNA, Messenger
(metabolism)
- Rats
- Rats, Wistar
- Reverse Transcriptase Polymerase Chain Reaction
- Tumor Necrosis Factor-alpha
(metabolism)
|